Palisade Bio, Inc. (PALI)

In October 2025, Palisade Bio closed a public offering, raising approximately $138 million and announced positive Phase 1b clinical data for PALI-2108, leading to a stock price increase. In December 2025, they announced a Japanese patent for PALI-2108 and strengthened their clinical leadership team, with Zacks Investment Research upgrading PALI to "Buy". In January 2026, Palisade Bio announced a strategic equity investment from the Crohn's & Colitis Foundation's IBD Ventures Program, and B Riley Securities initiated coverage with a "buy" recommendation, but the stock price fell by -0.526% on January 13, 2026, and has been down by -23.79% over the preceding 10 days.

As a clinical-stage biopharmaceutical company, Palisade Bio, Inc.'s products and services are in the development phase, primarily focused on clinical trials and regulatory approvals. Demand for its product candidates is driven by the successful progression through clinical development, regulatory approvals, and eventual market adoption rather than seasonal fluctuations.

Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for autoimmune, inflammatory, and fibrotic diseases, particularly GI disorders. Their lead candidate, PALI-2108, a prodrug PDE4 inhibitor, is in Phase 1a/b trials for ulcerative colitis and Phase 1a for fibrostenotic Crohn's disease. The company is also researching PALI-1908 and OB101/LB-1148, an oral drug candidate for GI inflammatory conditions and abdominal trauma.

Palisade Bio, Inc. is headquartered in Carlsbad, California, United States, with a presence in the United States. They have also received Health Canada clearance for a Phase 1b trial of PALI-2108 in fibrostenotic Crohn's disease, indicating clinical development activities in Canada.

Palisade Bio's brand reputation has been positively influenced by clinical development progress and analyst sentiment. Positive results from the Phase 1b trial of PALI-2108 for ulcerative colitis and Health Canada's approval for a clinical trial for fibrostenotic Crohn's disease have boosted the company's standing. Analyst ratings generally reflect a positive outlook, with a consensus rating of "Moderate Buy". A downturn in revenue over the last five years could be a point of concern for some investors.

Palisade Bio, Inc. has a concentrated ownership structure, with insiders holding approximately 90.65% of the company as of November 2025. Richard Garr is the largest individual shareholder, controlling 21.78% of the shares. Institutional investors also hold a substantial portion of the company's shares, with major holders including Two Sigma Securities, Llc, Geode Capital Management, Llc, UBS Group AG, Perceptive Advisors LLC, Commodore Capital LP, Point72 Asset Management, L.P., RA Capital Management, L.P., Fidelity Extended Market Index Fund (FSMAX), XTX Topco Ltd, Newbridge Financial Services Group, Inc., Morgan Stanley, Tower Research Capital LLC (TRC), Vanguard Extended Market Index Fund Investor Shares (VEXMX), and Fidelity Series Total Market Index Fund (FCFMX).